Both Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) are Biotechnology companies, competing one another. We will compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paratek Pharmaceuticals Inc.	5.17M	41.88	111.46M	-3.64	0.00
PhaseBio Pharmaceuticals Inc.	N/A	187.65	21.51M	-1.02	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Paratek Pharmaceuticals Inc. and PhaseBio Pharmaceuticals Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both businesses.

	Net Margins	Return on Equity	Return on Assets
Paratek Pharmaceuticals Inc.	-2,155.90%	-132.5%	-44.6%
PhaseBio Pharmaceuticals Inc.	0.00%	0%	0%

Liquidity

Paratek Pharmaceuticals Inc. has a Current Ratio of 11.4 and a Quick Ratio of 11.4. Competitively, PhaseBio Pharmaceuticals Inc.’s Current Ratio is 3.2 and has 3.2 Quick Ratio. Paratek Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than PhaseBio Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for Paratek Pharmaceuticals Inc. and PhaseBio Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Paratek Pharmaceuticals Inc.	0	1	1	2.50
PhaseBio Pharmaceuticals Inc.	0	0	0	0.00

The upside potential is 101.19% for Paratek Pharmaceuticals Inc. with consensus price target of $13.5.

Institutional & Insider Ownership

Institutional investors held 82.6% of Paratek Pharmaceuticals Inc. shares and 52.36% of PhaseBio Pharmaceuticals Inc. shares. Insiders held roughly 2.9% of Paratek Pharmaceuticals Inc.’s shares. Competitively, PhaseBio Pharmaceuticals Inc. has 0.1% of it’s share held by insiders.

Performance

In this table we show the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Paratek Pharmaceuticals Inc.	-9.11%	-11.05%	-31.2%	-36.88%	-61.02%	-61.56%
PhaseBio Pharmaceuticals Inc.	28.77%	-28.18%	0%	0%	0%	-26.6%

For the past year Paratek Pharmaceuticals Inc. was more bearish than PhaseBio Pharmaceuticals Inc.

Summary

PhaseBio Pharmaceuticals Inc. beats on 7 of the 10 factors Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.